Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895199 | 0.81 | ALDH1A1 (0.36) | LMNAKMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL647871 | 0.80 | IDO1 (0.38) | KMT2AMEN1ALDH1A1HPGDTSHR | |
| SCHEMBL1199895 | 0.79 | LMNA (0.48) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL3954839 | 0.77 | LMNA (0.39) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL8750384 | 0.76 | GABRA1 (0.38) | HPGDTSHRNPSR1L3MBTL1 | |
| SCHEMBL1200922 | 0.76 | LMNA (0.44) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL522410 | 0.75 | LMNA (0.36) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL548215 | 0.75 | KMT2A (0.48) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL12317473 | 0.75 | KMT2A (0.48) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL19418127 | 0.75 | IDO1 (0.50) | LMNAKMT2ATDP1MEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885KMT2A 2071/4885TDP1 3955/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885KMT2A 2071/4885TDP1 3955/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | LMNA 3238/4885KMT2A 2071/4885TDP1 3955/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885KMT2A 2071/4885TDP1 3955/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885KMT2A 2071/4885TDP1 3955/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885KMT2A 2071/4885TDP1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.